Cancer centers in the US have started enrolling patients for a worldwide Phase II study of roginolisib for metastatic uveal melanoma. Additionally, the Dana-Farber Cancer Institute has initiated a new trial of roginolisib for Chronic Lymphocytic Leukemia, supported by a grant from the Department of Defense. The study is taking place in multiple locations including Geneva and Amsterdam.